bioAffinity Technologies, Inc. Common Stock BIAF

$10.45 +58.60% at last close
Market Cap$3.90 million
P/E Ratio
Div Yield
Volume43.39M
52-Week Range $4.56$202.50

Key Stats

Today's Range
$7.54 $11.75
50-Day Range
$4.56 $13.05
52-Week Range
$4.56 $202.50
Volume
43.39 million shs
Average Volume
3.42 million shs
Market Cap
$3.90 million
P/E Ratio
Dividend Yield

Valuation

P/E Ratio
Price / Book
1.04
Price / Sales
0.66

Short Interest

Short Interest
1.46%
Days to Cover
1.00

Financials (TTM)

Revenue
$5.90 million
Net Income
$-15,185,242
Net Margin
-257.33%
Return on Equity
-402.92%
Debt-to-Equity

About bioAffinity Technologies, Inc. Common Stock

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
57
Exchange
XNAS
Listed
2022-09-01

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.